The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval is based primarily on the results from the pivotal randomized phase 3 RASolute 302 trial comparing daraxonrasib to chemotherapy as second-line therapy for patients with metastatic pancreatic cancer, led by Brian Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute.

The University of Texas MD Anderson Cancer Center today is recognizing the exceptional leadership of Peter WT Pisters, M.D., president, following his announced plan to retire from UT MD Anderson to focus on the next chapter of his career. The UT System Board of Regents and Chancellor John M. Zerwas, M.D., have named Jeffrey E. Lee, M.D., interim president, effective immediately. Pisters will work with Lee on a thoughtful transition through the end of September.

UC Berkeley scientists report the first analysis of the genomes of eight bats from the genus Myotis, known for having the longest-lived species — 50 years. The analysis finds a close link between bat longevity and its immune system — longer-lived bats had higher levels of cancer-fighting genes. The analysis suggests that an immune system able to mount an overwhelming attack against infectious organisms and cancer may be integral to a long lifespan.

Bats are anomalies in the mammalian world—they fly, have long lifespans, and rarely get cancer. Scientists now suspect the bat immune system enables them to live longer without disease, according to a new study published today in Nature.

Patients treated with medication for benign prostatic hyperplasia at the time of a severe acute heart attack experienced fewer serious complications from the attack, according to a study from the University of Gothenburg.

More than 1.9 million people are diagnosed with colorectal cancer each year, making it the third most common cancer and the second leading cause of cancer death worldwide. 

Global cancer burden continues to shift, driven by population aging, lifestyle changes, and disparities in screening and prevention.